scispace - formally typeset
U

Ulf Müller-Ladner

Researcher at University of Giessen

Publications -  644
Citations -  32784

Ulf Müller-Ladner is an academic researcher from University of Giessen. The author has contributed to research in topics: Medicine & Arthritis. The author has an hindex of 77, co-authored 590 publications receiving 27658 citations. Previous affiliations of Ulf Müller-Ladner include University of Regensburg & University of Genoa.

Papers
More filters
Journal ArticleDOI

A1.17 Analysis of two essential sub-processes of long distance migration of synovial fibroblasts from patients with rheumatoid arthritis

Birgit Zimmermann, +5 more
- 01 Mar 2014 - 
TL;DR: In vivo, in the SCID mouse implants, RASF can actively induce neovascularisation illustrated by a distinct pattern in vessel formation and could represent important steps for vascular transmigration relevant for R ASF long distance migration.
Journal ArticleDOI

S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes - Teil 1: Klassifikation, Diagnostik, Prävention und Aktivitätsscores.

Margitta Worm, +15 more
- 01 Aug 2021 - 
Journal Article

Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.

Gerd R Burmester, +9 more
- 07 Mar 2019 - 
TL;DR: CZP demonstrated efficacy and safety outcomes reflective of those observed in trial settings, and rapid reductions in disease activity and improvements in physical function were maintained up to wk 104.
Journal ArticleDOI

Einfluss serieller Radontherapie auf funktionale, funktionelle Parameter und das pro-inflammatorische Zytokinmilieu bei ankylosierender Spondylitis (AS)

Bernhard Kürten, +3 more
- 01 Aug 2010 - 
Journal ArticleDOI

FRI0268 Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from The Open-Label Period of The Fasscinate Trial

Dinesh Khanna, +11 more
- 01 Jun 2016 - 
TL;DR: Safety and safety in PBO-treated patients who switched to OL TCZ were generally similar to those observed in patients randomized to TCZ in the DB period, and results over 96 weeks of TCZ treatment suggest maintenance of the clinical response for mRSS in SSc patients.